


Supplementary Fig. S5



- **Stage 1:** Screening to determine eligibility for treatment (1-2 weeks)
- **Stage 2A:** LD chemotherapy: **fludarabine 30 mg/m² and cyclophosphamide 500 mg/m² IV daily for 3 days**
- **Stage 2B:**
 - CTX130 infusion as a **flat dose of CAR T cells**
 - Potential for redosing up to 2 times in subjects with CR/PR and evidence of PD, SD, or PD after significant clinical benefit
 - Redosing may occur at M2 based on Day 42 CT
- **Stage 3:** Follow-up (up to 5 years) after the last infusion of CTX130

Supplementary Fig. S5: COBALT-RCC trial design schematic. *CAR, chimeric antigen receptor; CR, complete response; CT, computed tomography; DLT, dose-limiting toxicity; IV, intravenous; LD, lymphodepleting; PD, progressive disease; PR, partial response; SD, stable disease.*